NO20061161L - Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel - Google Patents

Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel

Info

Publication number
NO20061161L
NO20061161L NO20061161A NO20061161A NO20061161L NO 20061161 L NO20061161 L NO 20061161L NO 20061161 A NO20061161 A NO 20061161A NO 20061161 A NO20061161 A NO 20061161A NO 20061161 L NO20061161 L NO 20061161L
Authority
NO
Norway
Prior art keywords
rosiglitazone
another anti
new preparation
diabetic agent
dosage form
Prior art date
Application number
NO20061161A
Other languages
English (en)
Inventor
Peter John Coles
Donald Colin Mackenzie
Jr Paul Norman Mudd
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27840010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061161(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of NO20061161L publication Critical patent/NO20061161L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet en oral doseringsform omfattende en eroderbar kjerne, hvilken kjerne omfatter rosiglitazon. eller et farmasøytisk akseptabelt salt eller solvat derav og et annet antidiabetisk middel, hvor kjernen har et belegg med en eller flere åpninger, kjennetegnet ved at belegget er eroderbart under på forhånd bestemte pH-betingelser, det er videre beskrevet en fremgangsmåte for fremstilling av en slik doseringsform og anvendelse av doseringsformen innenfor medisin.
NO20061161A 2003-08-11 2006-03-10 Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel NO20061161L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318824.0A GB0318824D0 (en) 2003-08-11 2003-08-11 Novel composition
PCT/EP2004/008970 WO2005013956A1 (en) 2003-08-11 2004-08-09 Novel composition comprising rosiglitazone and another antidiabetic agent

Publications (1)

Publication Number Publication Date
NO20061161L true NO20061161L (no) 2006-03-10

Family

ID=27840010

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061161A NO20061161L (no) 2003-08-11 2006-03-10 Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel

Country Status (36)

Country Link
US (1) US20080206336A1 (no)
EP (1) EP1663191B1 (no)
JP (1) JP4714147B2 (no)
KR (1) KR20060071396A (no)
CN (2) CN102397551A (no)
AP (1) AP2006003489A0 (no)
AR (1) AR045230A1 (no)
AT (1) ATE455542T1 (no)
AU (1) AU2004262933B2 (no)
BR (1) BRPI0413419A (no)
CA (1) CA2534480A1 (no)
CY (1) CY1109923T1 (no)
DE (1) DE602004025257D1 (no)
DK (1) DK1663191T3 (no)
EA (2) EA200800966A1 (no)
EC (1) ECSP066338A (no)
ES (1) ES2339554T3 (no)
GB (1) GB0318824D0 (no)
HR (1) HRP20100160T1 (no)
IL (1) IL173177A0 (no)
IS (1) IS2745B (no)
MA (1) MA27996A1 (no)
MX (1) MXPA06001629A (no)
MY (1) MY151053A (no)
NO (1) NO20061161L (no)
NZ (1) NZ544632A (no)
OA (1) OA13233A (no)
PE (1) PE20050357A1 (no)
PL (1) PL1663191T3 (no)
PT (1) PT1663191E (no)
SG (1) SG165178A1 (no)
SI (1) SI1663191T1 (no)
TW (1) TW200517146A (no)
UA (1) UA82537C2 (no)
UY (1) UY28461A1 (no)
WO (1) WO2005013956A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
AU2009270768A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
WO2011161521A1 (en) * 2010-06-21 2011-12-29 Lupin Limited Compositions comprising metformin and rosiglitazone
MY161846A (en) * 2010-07-09 2017-05-15 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
CN102727459A (zh) * 2011-04-15 2012-10-17 江苏豪森医药集团有限公司 一种具有第一和第二活性药物的制剂
CN118001246A (zh) * 2024-01-31 2024-05-10 四川鲁徽制药有限责任公司 一种达格列净、吡格列酮复方缓释片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
JP4533531B2 (ja) * 1998-04-03 2010-09-01 ビーエム リサーチ エイ／エス 制御放出組成物
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
DE69833179T2 (de) * 1998-11-10 2006-09-07 The Procter & Gamble Company, Cincinnati Bleichmittelzusammensetzungen
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
WO2001035940A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
WO2001082867A2 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
PE20030800A1 (es) * 2002-02-12 2003-10-31 Glaxo Group Ltd Forma de dosificacion oral de liberacion controlada
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Also Published As

Publication number Publication date
TW200517146A (en) 2005-06-01
OA13233A (en) 2006-12-13
MY151053A (en) 2014-03-31
UA82537C2 (uk) 2008-04-25
ECSP066338A (es) 2006-07-28
JP4714147B2 (ja) 2011-06-29
AU2004262933B2 (en) 2009-12-10
IS2745B (is) 2011-08-15
DE602004025257D1 (de) 2010-03-11
NZ544632A (en) 2009-03-31
KR20060071396A (ko) 2006-06-26
MA27996A1 (fr) 2006-07-03
IL173177A0 (en) 2006-06-11
GB0318824D0 (en) 2003-09-10
EA200800966A1 (ru) 2009-04-28
CN102397551A (zh) 2012-04-04
US20080206336A1 (en) 2008-08-28
ES2339554T3 (es) 2010-05-21
AU2004262933A1 (en) 2005-02-17
AR045230A1 (es) 2005-10-19
CY1109923T1 (el) 2014-09-10
CA2534480A1 (en) 2005-02-17
PL1663191T3 (pl) 2010-06-30
MXPA06001629A (es) 2006-04-28
CN1835741A (zh) 2006-09-20
WO2005013956A1 (en) 2005-02-17
DK1663191T3 (da) 2010-04-26
EA200600400A1 (ru) 2006-08-25
EA011550B1 (ru) 2009-04-28
EP1663191A1 (en) 2006-06-07
HRP20100160T1 (hr) 2010-05-31
BRPI0413419A (pt) 2006-10-10
IS8337A (is) 2006-03-02
SG165178A1 (en) 2010-10-28
JP2007501830A (ja) 2007-02-01
UY28461A1 (es) 2005-03-31
PE20050357A1 (es) 2005-06-01
EP1663191B1 (en) 2010-01-20
SI1663191T1 (sl) 2010-05-31
ATE455542T1 (de) 2010-02-15
CN1835741B (zh) 2011-12-14
AP2006003489A0 (en) 2006-02-28
PT1663191E (pt) 2010-03-16
HK1092051A1 (en) 2007-02-02

Similar Documents

Publication Publication Date Title
NO20061161L (no) Nytt preparat omfattende rosiglitazon og et annet anti-diabetisk middel
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
NO20053965L (no) Fremgangsmate for fremstilling av belagt preparat
NO331166B1 (no) Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene
NO20100250L (no) Farmasoytisk preparat som innbefatter en S1P reseptoragonist og en sukkeralkohol, og framgangsmate til fremstilling derav
DK1781260T4 (da) Tabletformulering med forlænget frigivelse indeholdende pramipexol eller et farmaceutisk acceptabelt salt deraf, fremgangsmåde til fremstilling deraf og anvendelse deraf
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
NO20080186L (no) Heterosykliske aspartylproteaseinhibitorer, fremstilling og anvendelse derav
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
EP1741712A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol
MX2025005474A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
JP2003507721A5 (no)
JP2008513426A5 (no)
AP1736A (en) Oral dosage form for controlled drug release.
DK1169029T3 (da) Anvendelse af sibutramin eller et derivat deraf til behandling af sövnforstyrrelser
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
JP2008513427A5 (no)
ECSP034469A (es) Compuesto farmaceutico novedoso
ES2323570T3 (es) Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina.
NO975790L (no) Anvendelse av allylaminderivater slik som terbinafin, i fremstillingen av et medikament for behandling av helikobacterpylori-infeksjonsassosierte sykdommer
NO20034985L (no) Nye 5-tio-SS-D-xylopyranosid-derivater, fremgangsmåte for fremstilling derav, farmasöytiske blandinger inneholdende dem og den terapeutiskeanvendelse derav
MY130814A (en) Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
DK1387837T3 (da) Hidtil ukendte azol- eller triazolderivater, fremgangsmåden til deres fremstilling og deres anvendelse som antimykotiske lægemidler
MXPA01009468A (es) Tratamiento de hipertension pulmonar.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application